OLFM4 Monoclonal Antibody (Clone 12)

Olfactomedin 4 (OLFM4) is a secreted olfactomedin domain-containing glycoprotein with roles in cell growth and apoptosis, tumor initiation and progression, and innate immunity.^1,2,3 It is composed of an N-terminal coil-coil domain and a C-terminal olfactomedin domain and expressed in the small intestine, colon, prostate, stomach, and bone marrow, as well as macrophages and in neutrophils within specific granules.^4,1 Olfm4 knockdown decreases renal cell apoptosis and increases survival in a mouse model of sepsis and increased blood levels of OLFM4 are associated with poor outcomes in patients with sepsis.² Levels of OLFM4 are increased in intestinal tissue isolated from neonatal patients with necrotizing enterocolitis.¹ OLFM4 levels are decreased in metastatic cervical cancer tissues compared with adjacent non-cancerous tissues isolated from patients with cervical cancer.³ Cayman’s OLFM4 Monoclonal Antibody can be used for ELISA and flow cytometry (FC) applications.

WARNING This product is not for human or veterinary use.

1. Diez, S., Renner, M., Bahlinger, V., et al. Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: An observational research study. BMC Pediatr. 22(1), 192 (2022).

2. Stark, J.E., Opoka, A.M., Mallela, J., et al. Juvenile OLFM4-null mice are protected from sepsis. Am. J. Physiol. Renal Physiol. 318(3), F809-F816 (2020).

3. Li, J., Liu, C., Li, D., et al. OLFM4 inhibits epithelial–mesenchymal transition and metastatic potential of cervical cancer cells. Oncol. Res. 27(7), 763-771 (2019).

4. Grover, P.K., Hardingham, J.E., and Cummins, A.G. Stem cell marker olfactomedin 4: Critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29(4), 761-775 (2010).